TECVAYLI® + DARZALEX FASPRO® combination regimen significantly improves PFS and OS vs SOC October 21, 2025
Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of RRMM Announced October 7, 2025
Ph 3 EXCALIBER-RRMM Study of Iberdomide-SOC combo Demonstrated a Significant Improvement in MRD Negativity Rates in RRMM September 30, 2025
ACT appointed for POLB 001 Ph 2a Trial and supply of approved bispecific antibody drug secured at no cost September 30, 2025
100% MRD negativity seen in Ph 2 MajesTEC-5 study of TECVAYLI & DARZALEX FASPRO induction in transplant-eligible 1L multiple myeloma September 23, 2025
Initial patients dosed in multiple cohorts of Ph 1 dose-expansion study of KTX-1001, mezigdomide, and SoC combo in t(4;14) multiple myeloma September 23, 2025
First Patient Dosed in Ph 1 inMMyCAR Study of in vivo CAR T-cell Therapy for RRMM patients August 26, 2025
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma July 29, 2025
US FDA extends review period for Blenrep (belantamab mafodotin-blmf) in R/R multiple myeloma July 29, 2025
Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma July 29, 2025
Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma July 29, 2025
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma July 29, 2025
FDA ODAC voted against the overall benefit/risk profile of Blenrep (belantamab mafodotin-blmf) combo in R/R multiple myeloma July 23, 2025
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for First-in-Class CD38×BCMA×CD3 Trispecific Antibody ISB 2001 July 15, 2025
Lynozyfic (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of R/R Multiple Myeloma July 8, 2025
DARZALEX® (daratumumab) receives positive CHMP opinion for patients with high-risk smouldering multiple myeloma July 1, 2025
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma June 24, 2025
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95% PFS at four years in transplant-eligible 1L multiple myeloma patients who achieved sustained MRD negativity June 10, 2025
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in RRMM patients June 10, 2025
FDA ODAC votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma May 27, 2025
